Michael Perlis, Ph.D.
Director of Behavioral Sleep Medicine Program, Associate Professor
University of Pennsylvania Perelman School of Medicine
Michael L. Perlis, PhD is internationally known for his work in the area of Behavioral Sleep Medicine (BSM). He is a coauthor of the first text book in this field and he is the senior author of a published CBT-I treatment manual and a larger text summarizing all BSM treatments. His research includes neurocognitive phenomena in insomnia, the cognitive and/or behavior effects of sedative hypnotics and placebos, the development of alternative treatment approaches for insomnia, and sleep in depression. His work has been, and continues to be, funded by the National Institutes of Health and he has published more than 100 articles and chapters on the sleep research related topics.
In addition to his academic endeavors, he has served on the editorial boards of Sleep, the Journal of Sleep Research, the journal of Sleep Medicine Research and the journal of Behavioral Sleep Medicine. Dr. Perlis has also served as a member, or chair, of several committees and task forces of the Sleep Research Society and the American Academy of Sleep Medicine and he was a founding member of the Society of Behavioral Sleep Medicine and served as the society's first president (2010-2011).
Financial: Financial: Michael Perlis has employment relationships with the University of Freiburg and the University of Pennsylvania. He receives royalties as a published author. Michael Perlis receives a consulting fee from Anavex Life Sciences and Nexalin Technology. He receives grants Jazz Pharmaceuticals. Michael Perlis receives a speaking honorarium and recording royalties from PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.
Non-financial: Michael Perlis is a member of the Sleep Research Society, the Association for Behavioral & Cognitive Therapy, and the American Academy of Sleep Medicine. He serves on several editorial boards, for a complete list contact PESI, Inc.